ARCHIVES

Ivax Paclitaxel To Remain On Market In Deal With BMS.

This article is from The Cancer Letter archive.

Vol. 28 No. 05 | February 1, 2002

Download PDF Visit The Full Archive

Related Articles

Final Issue Of 1992

December 11, 1992

Working Group To Review NCI Clinical Trials Programs

April 12, 1996

In Brief: NCAB to Hear Program Review, Reports On AIDs Monoclonal Antibodies, Cancer Research at Drew

November 25, 1983

RFA On Breast Tumor Factors Patients Survival

June 20, 1980

NCI Should Examine Alternative Therapies TA Report Says

September 28, 1990

Second Irregularity In NSABP Data Found; Fisher Takes Leave As Group’s Chairman

April 1, 1994